No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Monday, October 6, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Pharma Stock to Buy for Long Term Growth?

by TheAdviserMagazine
6 months ago
in Business
Reading Time: 4 mins read
A A
Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Pharma Stock to Buy for Long Term Growth?
Share on FacebookShare on TwitterShare on LInkedIn


We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) stands against other best pharma stocks to buy for long term growth.

With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before. About 30% of Big Pharma acquisitions involving at least $50 million upfront in 2024 involved Chinese corporations, according to DealForma statistics, as reported by CNBC. This was an increase from 20% the previous year and nearly 0% just five years before.

Experts cite several causes for this tendency. Some people think that Chinese pharmaceutical firms are drawing notice due to their sophisticated development skills, which enable them to produce potent compounds in large quantities. In addition to being able to start testing on human subjects more quickly, these Chinese companies can charge a lower price for these medications than the US. Buyers have developed a business strategy that enables them to import medicines through licensing agreements, according to CNBC. The dearth of venture capital in China is additional pressure on biotech companies to enter these agreements.

Experts think this situation is here to stay, even though there are several possible causes for this tendency. Although the US pharmaceutical industry is expected to be impacted, it is uncertain how these effects would manifest. If big pharmaceutical companies find a good Chinese drug at a low price, some experts think it may destroy American startups; others think the competition would benefit the sector. Tim Opler, a managing director in Stifel’s global healthcare group, stated the following regarding the circumstances:

“It’s kind of a watershed moment where the pharma industry is like, ‘We don’t really need to buy U.S. biotechs necessarily. We will if it makes sense, but we can buy perfectly good biotech assets through licensing deals with Chinese companies.”

Emily Field, Head of European Pharma Research at Barclays, spoke to CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical industry. According to her, at least in the first half of this year, the industry might not perform poorly. The effectiveness of obesity medications is still up for debate, though, as leading companies in the field have shown inconsistent results in the past.

Story Continues

Speaking about the tariffs, she stated that since some businesses assemble their products in the US after producing them overseas, their implementation raises several unanswered questions for the pharmaceutical industry. These businesses, therefore, have relatively low manufacturing costs, which is an important factor to take into account when assessing the effects of tariffs. She thought that these businesses could easily absorb the higher expense of the tariffs. The topic hasn’t come up much on earnings calls this quarter, and the market is nearing the end of the reporting season.

For this article, we screened for companies that operate in the pharmaceutical industry. From that list, we identified stocks that have achieved positive revenue growth over the past five years. Then, we picked companies with a 5-year revenue growth of 10% and ranked the top 10 based on hedge fund sentiment as of Q4 2024, as per Insider Monkey’s database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Pharma Stock to Buy for Long Term Growth?

A close-up of a woman’s hand syringe containing a bio-pharmaceutical drug.

Number of Hedge Fund Holders: 23 

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a biopharmaceutical company that specializes in the development, manufacturing, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company operates primarily in the United States, China, and France.

In the third quarter of 2024, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) reported net revenues of $191.2 million, a 6% increase from the previous year. The introduction of Primatene Mist ($26.1 million), Baqsimi ($40.4 million), and Albuterol MDI ($40.4 million) was credited by the firm with this growth. Primatene Mist is on track to surpass $100 million in annual sales by the end of 2024, and the business plans to expand the Baqsimi market and strengthen its sales team, positioning itself tenth among the best pharmaceutical stocks to watch.

Despite a drop in adjusted net income to $49.6 million ($0.96 per share) due to lower gross margins (53% vs. 60% in 2023) and higher operating expenses, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) generated $60 million in cash flow and repurchased $35 million worth of shares. Additionally, the company initiated a $50 million share buyback program. Ongoing discussions with the FDA over its insulin pipeline are expected to fuel future growth.

As of Q4 2024, 23 hedge funds held stakes in the stock, as tracked by the Insider Monkey database.

Overall, AMPH ranks 10th on our list of best pharma stocks to buy for long term growth. While we acknowledge the potential of pharmaceutical companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than AMPH but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.



Source link

Tags: AMPHAmphastarBuygrowthLongPharmaPharmaceuticalsstockterm
ShareTweetShare
Previous Post

Alphabet: Diese Kursmarke müssen die Bullen verteidigen!

Next Post

Bank of America (BAC) earnings Q1 2025

Related Posts

edit post
Oil prices gain 1% after lower-than-expected OPEC+ output hike

Oil prices gain 1% after lower-than-expected OPEC+ output hike

by TheAdviserMagazine
October 5, 2025
0

Oil prices rose about 1% in early trade on Monday after OPEC+ announced a more modest monthly increase in production...

edit post
Bulls piling into emerging markets as momentum returns

Bulls piling into emerging markets as momentum returns

by TheAdviserMagazine
October 5, 2025
0

Emerging market assets look set to cap a banner year, with investors expecting inflows into equities and bonds to gain...

edit post
Dollar vs yen: Surprise in Japan’s leadership race to roil financial markets

Dollar vs yen: Surprise in Japan’s leadership race to roil financial markets

by TheAdviserMagazine
October 5, 2025
0

An unexpected result in Japan’s leadership contest over the weekend is poised to ripple through global financial markets with the...

edit post
Firefly Aerospace strengthens portfolio with 5 million deal for national security tech firm SciTec

Firefly Aerospace strengthens portfolio with $855 million deal for national security tech firm SciTec

by TheAdviserMagazine
October 5, 2025
0

(Reuters) -Space tech firm Firefly Aerospace will acquire national security technology company SciTec for about $855 million. The deal, which...

edit post
Taylor Swift’s ‘Show Girl’ smashes The Rock’s ‘Smashing Machine’

Taylor Swift’s ‘Show Girl’ smashes The Rock’s ‘Smashing Machine’

by TheAdviserMagazine
October 5, 2025
0

It might have looked like a heavyweight matchup, but Swift’s devoted fanbase once again proved unstoppable with her film “The Official Release...

edit post
Larry Summers praises Ford CEO Jim Farley’s concept of the essential economy because it doesn’t ‘fetishize manufacturing’

Larry Summers praises Ford CEO Jim Farley’s concept of the essential economy because it doesn’t ‘fetishize manufacturing’

by TheAdviserMagazine
October 5, 2025
0

Former Treasury Secretary Larry Summers said Ford CEO Jim Farley’s idea of the “essential economy” is a good concept as...

Next Post
edit post
Bank of America (BAC) earnings Q1 2025

Bank of America (BAC) earnings Q1 2025

edit post
Citi wealth client assets surge in first quarter

Citi wealth client assets surge in first quarter

  • Trending
  • Comments
  • Latest
edit post
What Happens If a Spouse Dies Without a Will in North Carolina?

What Happens If a Spouse Dies Without a Will in North Carolina?

September 14, 2025
edit post
California May Reimplement Mask Mandates

California May Reimplement Mask Mandates

September 5, 2025
edit post
Does a Will Need to Be Notarized in North Carolina?

Does a Will Need to Be Notarized in North Carolina?

September 8, 2025
edit post
DACA recipients no longer eligible for Marketplace health insurance and subsidies

DACA recipients no longer eligible for Marketplace health insurance and subsidies

September 11, 2025
edit post
‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

September 9, 2025
edit post
Tips to Apply for Mental Health SSDI Without Therapy

Tips to Apply for Mental Health SSDI Without Therapy

September 19, 2025
edit post
Massachusetts OBBBA Conformity | Tax Foundation

Massachusetts OBBBA Conformity | Tax Foundation

0
edit post
Decision Attribution: Portfolio Manager Skill vs. Past Performance

Decision Attribution: Portfolio Manager Skill vs. Past Performance

0
edit post
The ,000 Day Trading Rule May Soon Go Away

The $25,000 Day Trading Rule May Soon Go Away

0
edit post
Heidi Health raises M Series B led by Steve Cohen’s Point72

Heidi Health raises $65M Series B led by Steve Cohen’s Point72

0
edit post
Inside An E-Commerce Giant’s Threat Intelligence Strategy

Inside An E-Commerce Giant’s Threat Intelligence Strategy

0
edit post
BitFuFu (FUFU) Emphasizes Transparency and Security in Cloud Mining Operations

BitFuFu (FUFU) Emphasizes Transparency and Security in Cloud Mining Operations

0
edit post
Millions Sign Petition To Dismantle UK Digital ID System

Millions Sign Petition To Dismantle UK Digital ID System

October 6, 2025
edit post
Heidi Health raises M Series B led by Steve Cohen’s Point72

Heidi Health raises $65M Series B led by Steve Cohen’s Point72

October 6, 2025
edit post
Inside An E-Commerce Giant’s Threat Intelligence Strategy

Inside An E-Commerce Giant’s Threat Intelligence Strategy

October 5, 2025
edit post
Russia Rejects Anti-Dollar Claims as Putin Defends BRICS Trade Strategy

Russia Rejects Anti-Dollar Claims as Putin Defends BRICS Trade Strategy

October 5, 2025
edit post
Oil prices gain 1% after lower-than-expected OPEC+ output hike

Oil prices gain 1% after lower-than-expected OPEC+ output hike

October 5, 2025
edit post
Stablecoin-Focused GENIUS Act Is Beginning of the End for Banks

Stablecoin-Focused GENIUS Act Is Beginning of the End for Banks

October 5, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Millions Sign Petition To Dismantle UK Digital ID System
  • Heidi Health raises $65M Series B led by Steve Cohen’s Point72
  • Inside An E-Commerce Giant’s Threat Intelligence Strategy
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.